The pathogenesis of Hodgkin's disease.
Extensive clinical research over the past few decades has changed Hodgkin's disease from a routinely fatal disease to a usually curable disease. However, treatment is far from perfect; a substantial percentage of patients are not cured of their primary disease, and a substantial percentage of patients die of treatment-related second malignancies. Present efforts in clinical research are likely to result in improved antitumor therapy and a reduction in second malignancies; however, it is unrealistic to expect that they will result in striking improvements. Major new advances in Hodgkin's disease will require a better understanding of the biology of the disease.
Collins
R H
RH
University of California, School of Medicine, Department of Medicine, Los Angeles 90024-1678.
D000943:Antigens, Differentiation / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D001685:Biological Factors / Q000096:biosynthesis; D014408:Biomarkers, Tumor / Q000032:analysis; D002999:Clone Cells / Q000473:pathology; D016207:Cytokines; D006689:Hodgkin Disease / Q000209:etiology* / Q000235:genetics / Q000382:microbiology / Q000473:pathology; D006801:Humans; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000209:etiology; D008954:Models, Biological; D014411:Neoplastic Stem Cells / Q000473:pathology; D014777:Virus Diseases / Q000150:complications
D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D001685:Biological Factors; D014408:Biomarkers, Tumor; D016207:Cytokines